08.10.2014 14:40:36
|
Salix Pharma: FDA Approves UCERIS Rectal Foam - Quick Facts
(RTTNews) - Salix Pharmaceuticals, Ltd. (SLXP) announced the FDA has granted final approval for UCERIS (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis extending up to 40cm from the anal verge.
On September 15, 2014 the FDA tentatively approved UCERIS rectal foam pending expiration of the 45-day waiting period. The waiting period has expired and the FDA has granted UCERIS rectal foam final approval as of October 7, 2014.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Salix Pharmaceuticals Ltd.mehr Nachrichten
Keine Nachrichten verfügbar. |